ENGN · ISSUER CIK 1980845
enGene Therapeutics Inc.
Between Aug 1, 2026 and Oct 29, 2026, 1 enGene Therapeutics Inc. insiders reported $10K of open-market purchases and $0.00 of sales on SEC Form 4. The largest buyer was Grossman William (Interim Chief Medical Officer, Director), with $10K.
↗1 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. No open-market sales in the window.
$10KInsider buying
$0.00Insider selling
+$10KNet open-market
Sep 24, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 24, 202616:40 | Sep 22, 2026 | ENGN | Interim Chief Medical Officer, Director | P · Buy | $1.97 | +5,102 | 5,102 | New | +$10K | +0.5% | -22.3% |